Oliver Wright

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Peter Hillmen, Tadeusz Robak, Ann Janssens et al. · The Lancet · 2015 · 337 citations

Hematological Malignancy, Immunohematology, Complement 1 +13

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

Steven M. Grunberg, Janusz Rolski, János Strausz et al. · The Lancet Oncology · 2009 · 68 citations

Emetogenic Chemotherapy, Oncology, Chemotherapy-induced Nausea +9

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

Paul J. Hesketh, Oliver Wright, Gerardo Rosati et al. · Supportive Care in Cancer · 2011 · 32 citations

Drug Safety, Translational Medicine, Pharmacology +7

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Ian W. Flinn, Panayiotis Panayiotidis, Boris V. Afanasyev et al. · American Journal of Hematology · 2016 · 25 citations · Full text

Pharmacotherapy, Metronomic Chemotherapy, Immunotherapy +18

Effects of treadmill training on microvascular remodeling in the rat after spinal cord injury

Roger W. P. Kissane, Oliver Wright, Yazi D. Al'Joboori et al. · Muscle & Nerve · 2018 · 23 citations